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Available online 12 July 2017Many neurodegenerative disorders, including Alzheimer's, Parkinson's and the prion diseases, are characterized
by a conformational conversion of normally soluble proteins or peptides into pathological species, by a process of
misfolding and self-assembly that leads ultimately to the formation of amyloid fibrils. Recent studies support the
idea that multiple intermediate species with a wide variety of degrees of neuronal toxicity are generated during
such processes. The development of a high level of knowledge of the nature and structure of the pathogenic am-
yloid specieswould significantly enhance efforts to underline themolecular origins of these disorders and also to
develop both accurate diagnoses and effective therapeutic interventions for these types of conditions. In this re-
view, we discuss recent biophysical and structural information concerning different types of amyloid aggregates
and the way in which such information can guide rational therapeutic approaches designed to target specific
pathogenic events that occur during the development of these highly debilitating and increasingly common
diseases.
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Amyloid formation refers to the process by which soluble, typically
monomeric, peptides and proteins misfold and self-assemble into amy-
loid fibrils (Fig. 1). Amyloid fibrils are thread-like structures typically
composed of several protofilaments with a common architecture,
termed the cross-β structure (Eisenberg and Jucker, 2012; Fandrich
and Dobson, 2002; Fitzpatrick et al., 2013; Jimenez et al., 1999;
Sawaya et al., 2007; Sunde et al., 1997), which is largely independentect.com).
Inc. This is an open access article uof the amino acid sequence and native fold of the protein of which the
fibrils are composed. This ability to form this structure has indeed
been recognized to be a generic property of the polypeptide chain
(Dobson, 1999, 2003).
For over a century, amyloid formation has been recognized as a hall-
mark of a number of medical disorders, particularly neurodegenerative
diseases. Currently, approximately 50 distinct human diseases and disor-
ders (Chiti and Dobson, 2017), some of them among the most common
and debilitating medical conditions in the modern world, including
Alzheimer's (AD) and Parkinson's disease (PD), have been linked with
the accumulation of amyloid deposits, which are primarily composed of
one specific type of peptide or protein depending on the particular disor-
der. Such conditions are collectively referred to as protein misfolding or
amyloid diseases (Chiti and Dobson, 2006). Despite the well-establishednder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic representation of the process of amyloid formation. Natively folded or unfolded proteinmolecules, typically inmonomeric form, undergo a process ofmisfolding and
self-assembly generating initially oligomeric species and eventually amyloid fibrils. Once formed, these fibrils tend to accumulate into protein-rich inclusions that are the hallmark of a
wide range of disease conditions. Although the general mechanism of amyloid formation has been established, the details of the formation, and conversion between the various
species that are involved, along with their structures and properties, are still an important topic of investigation for specific proteins, under different conditions.
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pathology in these conditions, much remains to be learnt about the mo-
lecular origins of amyloid formation and the specific mechanisms under-
lying the toxicity associated with these processes.
The pathogenicity of amyloid formation has been associated with a
loss of function of the proteins that aggregate, but more generally
with a gain of toxic function through the generation and accumulation
of misfolded aggregated forms of the protein. The localization of protein
inclusions in the damaged regions of patients suffering from amyloid
diseases led initially to the hypothesis that the fibrillar species of
which the inclusions are largely composed were the toxic agents re-
sponsible for pathogenicity in these diseases (Yankner et al., 1990).
This may be the case for at least some systemic amyloidoses, in which
large quantities of amyloid aggregates are deposited in vital organs
(Chiti and Dobson, 2006). In other amyloid diseases, however, including
most neurodegenerative disorders, there is a lack of a direct correlation
between the extent of accumulation of protein inclusions and the se-
verity of disease-associated symptoms, suggesting that other forms
of aggregated proteins may be giving rise to neurodegeneration
(Kalia et al., 2013; Ross and Poirier, 2005). Indeed, it is becoming
evident from in vitro and in vivo experiments, and from analysis of
biofluids from human patients, that some forms of oligomeric spe-
cies could play an important role in these diseases (e.g. for proteins
such as Aβ (Shankar et al., 2008; Townsend et al., 2006), tau
(Lasagna-Reeves et al., 2012; Patterson et al., 2011), huntingtin
(Nekooki-Machida et al., 2009) and α-synuclein (Cremades et al.,
2012; Horrocks et al., 2016; Kalia et al., 2013; Tsigelny et al., 2008;
Winner et al., 2011). Such conclusions are also consistent with the
hypothesis of generic effects of prefibrillar aggregates, even when
the aggregates are not related with any known disease (Bucciantini
et al., 2002; Dobson, 2003).
An increase in our detailed knowledge of the nature and structure of
the pathogenic amyloid species and the details of their mechanisms of
toxicity would be of very great value in the rational design of effective
therapeutic strategies against these devastating diseases, for which
there are still no effective treatments. In the last two decades, the phar-
maceutical industry has devoted substantial resources into programs to
develop drugs against AD and PD, primarily focused on the ‘amyloid cas-
cade’ hypothesis. A variety of drug candidateswith a diversity of molec-
ular targets have been tested in clinical trials, some of them designed to
inhibit the aggregation process, some to promote the removal of amy-
loid deposits, and some to modulate the transport of the amyloid pro-
tein precursors between the central nervous system and the
peripheral circulation (Folch et al., 2016). However, almost none of
the drug candidates tested so far has shown any significant efficacy or
succeeded in clinical trials (see for example (Folch et al., 2016)).Immunotherapy using antibodies against a specific amyloidogenic
protein, also referred to as immunomodulation throughpassive immuni-
zation, has been suggested as a potential therapeutic treatment for amy-
loid diseases in recent years (see for example (Valera et al., 2016)),
particularly since the recognition that toxic amyloid aggregates can be
involved in the spread and propagation of the neurodegenerative pro-
gression of disease by means of a ‘prion-like’ mechanism (i.e. through
the spatial propagation of amyloid assemblies from cell to cell coupled
with seeding and secondary processes) (Brundin et al., 2010; Danzer et
al., 2009; Jucker andWalker, 2013; Luk et al., 2012). In the case of extra-
cellular peptides and proteins such as the Aβ peptide, involved in AD, it
has been suggested that amyloid aggregates can be taken up by adjacent
neuronal cells, leading to pathological propagation, while for intracellu-
lar proteins such as α-synuclein (αS), linked to PD, the initially generat-
ed intracellular aggregates are assumed to enter the extracellular space
and then to be taken up by neighbouring cells (Holmes and Diamond,
2012; Luk et al., 2012; Peelaerts et al., 2015; Volpicelli-Daley et al.,
2011). Thus immunotherapy aiming to reduce the level of extracellular
toxic amyloid aggregates, or preventing them from entering cells and
spreading into new regions, could be a promising therapeutic strategy
to prevent the progression of pathology (Mandler et al., 2015;
Sankaranarayanan et al., 2015; Tran et al., 2014; Valera and Masliah,
2016). Indeed, preclinical studies have shown that passive immunization
with this aim reduces cerebral amyloid load, improves cognition, and
mitigates neurodegeneration in mouse models (Bard et al., 2000; Kalia
et al., 2013; Oddo et al., 2004; Wilcock et al., 2004).
One current limitation of such immunotherapy approaches is that
many of the antibodies that have been developed and are under inves-
tigation do not discriminate between different types of protein aggre-
gates and are typically raised against, or preferentially bind to, the
monomeric form of the protein (Goure et al., 2014). As this is typically
the biologically active form of the protein, however, the binding to an
antibody can potentially perturb very significantly its biological func-
tion. In addition, viable dosages of these antibodies may be saturated
by the high levels of the monomeric form of the protein relative to the
pathogenic forms present in vivo. Indeed, preferential binding to the
monomeric form of the protein may be a significant contributor to the
failure of clinical trials to show improvement of disease symptoms
(Doody et al., 2014; Goure et al., 2014). Taken together, these studies
have suggested that non-specific targeting, or the targeting of mono-
mers, is unlikely to be effective in a clinical setting, and much efforts
have been devoted for the development of immunotherapies that can
selectively target the most highly toxic amyloid species (see for exam-
ple (Folch et al., 2016)). Antibodies that target a region of the peptide
sequence may, however, prove to have low efficacy, as they may
cross-react with multiple forms of the amyloidogenic polypeptide
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formational or structurally specific antibodies (De Genst et al., 2014;
Kayed et al., 2007, 2003; Perchiacca et al., 2012) could be the key to
targeting specific toxic aggregated forms provided it becomes possible
to develop structurally specific antibodies that are able to differentiate
between aggregate polymorphs or strains of the same protein; in this
way it may be possible to target selectively different pathological fea-
tures that occur during the development of a particular amyloid disease.
2. Amyloid formation and neurodegenerative disorders
The amyloid cascade hypothesis was put forward in the 1990s and
suggested that the formation and accumulation of fibrillar amyloid ag-
gregates is the primary origin of the pathogenesis of AD (Hardy and
Higgins, 1992; Yankner et al., 1990). This hypothesis emerged from
the recognition that amyloid fibrillar forms of the Aβ peptide are a com-
mon feature of AD patients (Glenner and Wong, 1984; Masters et al.,
1985). Since then, the aggregation of more than 30 peptides and pro-
teins have been linked with other amyloid diseases (in some cases the
same protein is involved in multiple diseases), with a significant num-
ber involved in brain diseases, notably neurodegenerative disorders
(Chiti and Dobson, 2006; Knowles et al., 2014). Indeed, it is well
established that over-production or imbalance in the generation/degra-
dation of a specific amyloidogenic peptide or protein plays a role in neu-
rodegeneration and the development of disease (Mucke, 2009).
Additional support for this hypothesis came later from genetics,
where single point mutations in the various genes that encode specific
amyloidogenic proteins could be linked with the onset of familial
forms of disease, particularly in the case of AD and PD (Bekris et al.,
2010; Klein and Westenberger, 2012). In most of these familial cases,
fortunately relatively rare, there is early onset of the disease but the
pathophysiology is essentially identical to that of the sporadic, late-
onset forms (Bekris et al., 2010; Goate et al., 1991; Klein and
Westenberger, 2012). A significant number of mutations have now
been observed in the genes that encode the amyloid precursor protein
(APP) and αS that are associated with early-onset familial cases of AD
and PD, respectively, andmost of them have been related to an increase
in either the levels of the amyloidogenic protein or in its aggregation
propensity (Irvine et al., 2008).
In the case of αS, in addition to familial mutations, duplication and
triplication of the αS gene can occur, resulting in increased levels of
the wild type protein that are sufficient to cause autosomal dominant
early-onset forms of PD (Klein and Westenberger, 2012). Although
these familial cases account for only a small fraction of PD in the general
population, the Lewy bodies and Lewy neurites observed both in famil-
ial and idiopathic PD stain strongly forαS (Galvin et al., 1999; Spillantini
et al., 1998; Spillantini et al., 1997). In addition, a genome-wide associ-
ation study has shown that individuals with certain polymorphisms of
the gene that encodes for αS have a higher risk of developing sporadic
PD (Seidel et al., 2010), and someof these polymorphismshave been as-
sociated with higher expression levels ofαS in neurons (Maraganore et
al., 2006). In an analogousway, internal chromosome21 duplications or
triplication of chromosome 21 in Down syndrome that results in over-
expression of the APP has also been linked with brain pathology and
higher risks of early-onset AD (Head et al., 2012). Conversely, partial tri-
somy of chromosome 21 that does not result in extra APP gene does not
lead to AD (Sleegers et al., 2006). It is clear, therefore, in bothAD and PD,
that an increase in quantities of the amyloidogenic protein results in an
increased risk of the onset of disease.
Although it iswidely known andwell established that aggregation of
a particular protein is the hallmark of each of these types of disease (and
amyloid pathology is observed in all cases), and that there is a direct ge-
netic link between amyloidogenic proteins and the development of dis-
ease, the relationship between amyloid deposition with cognitive
decline is a subject of intense debate in the field. Indeed, the amount
and location of the amyloid inclusions do not always correlate withneuronal loss (Delacourte et al., 1999; Gomez-Isla et al., 1996), and
the recent clinical failures of potential AD drugs targeting the Aβ pep-
tide have intensified scrutiny of the amyloid cascade hypothesis. As a re-
sult, alternative hypotheses have been suggested for the onset and
progression of AD and PD, such as themitochondrial cascade hypothesis
(see review (Swerdlow et al., 2014)) or the metabolism hypothesis
(Hoyer, 1991; Hoyer et al., 1988). None of these ideas, however, suc-
ceeds in reconciling individually all of the experimental and clinical as-
pects of these types of disease.
An alternative to the amyloid cascade hypothesis that has currently
gained significant momentum is one in which low molecular weight
oligomers generated during the formation of the amyloid fibrils repre-
sent key neurotoxic agents that cause neurodegeneration (Chiti and
Dobson, 2006; Dobson, 2003; Walsh and Selkoe, 2007). Oligomeric
forms of amyloid aggregates have been detected in the brains and tis-
sues of patients suffering from neurodegenerative disorders and grow-
ing experimental evidence suggests that certain oligomeric forms of
amyloidogenic proteins are inherently more damaging than their fibril-
lar counterparts, and are believed to be the primary origins of the toxic-
ity associatedwith amyloid diseases (Arrasate et al., 2004; Bucciantini et
al., 2002; Haass and Selkoe, 2007; Winner et al., 2011). The nature of
their particular toxic activity has been long hypothesized to arise from
a set of unique structural features characteristic of these species that
are absent in the monomeric and in the fibrillar amyloid forms
(Evangelisti et al., 2016; Kayed et al., 2003), in combination with their
diffusive capabilities as a result of their relatively small size, which
could lead them to mediate toxic effects at regions distant from the lo-
cation of the amyloid plaques. Important evidence for a toxic role of am-
yloid oligomers comes from studies where some single point mutations
in the amyloidogenic polypeptides, some of them related with familial,
early onset forms of the disease, have been shown to favour the accu-
mulation of oligomeric rather than fibrillar aggregates and to show a
more toxic behaviour in vivo (Goate et al., 1991; Winner et al., 2011).
In addition, oligomeric forms of Aβ andαS have been shown to promote
amyloid aggregation and deposition (Cohen et al., 2013; Walker and
Jucker, 2015) and have been suggested to propagate between cells in
a prion-like manner (Ye et al., 2015). Although the identity of the
most pathological forms of amyloid assemblies is still a subject of in-
tense debate in the field, particularly in the recent years (Luk et al.,
2012; Peelaerts et al., 2015; Prusiner et al., 2015; Woerman et al.,
2015), the causal role of amyloidogenic proteins in neurodegenerative
diseases is widely considered to involve soluble amyloid oligomers.
3. Neuronal toxicity of amyloid species
Aberrant folding and aggregation of certain amyloidogenic proteins
has been suggested to be the initial trigger of amyloid diseases that is
then followed byother events, such as calciumandmetal ion imbalance,
oxidative stress, and the overload of chaperone and ubiquitin protea-
some systems (Irvine et al., 2008; Ross and Pickart, 2004). The generic
ability of proteins to undergo similar conformational transitions
resulting in the acquisition of a characteristic self-assembled β-sheet
rich structure, albeit displaying differences in size and overall morphol-
ogy, points to common pathways of aggregation with commonmecha-
nisms of toxicity (Bucciantini et al., 2002; Dobson, 1999).
Three distinct pools of protein species can be distinguished once the
self-assembly process has been triggered: monomers, soluble oligo-
mers, and insoluble fibrillar species (Fig. 1). Each of these pools encom-
passes an array of individual species, particularly in the case of soluble
oligomers, which globally can show very high heterogeneity in terms
of size and structure. While neither monomeric Aβ nor αS has been re-
ported so far to possess any direct cellular toxicity under physiologically
relevant concentrations, amyloid aggregates generated by these two
polypeptides have been shown to exhibit substantial neurotoxicity
(Knowles et al., 2014). A significant number of studies have proposed
that amyloid plaques and insoluble fibrillar aggregates of both Aβ and
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be actually beneficial as an in vivomechanism for removal of the more
toxic soluble oligomers (Baglioni et al., 2006; Cheng et al., 2007;
Dobson, 2003; Treusch et al., 2009). In contrast, since the first sugges-
tion that soluble oligomeric species rather than fibrillar plaques could
trigger neurotoxicity, many studies have shown that soluble oligomers
are themost toxic forms of amyloidogenic proteins, able to induce neu-
rodegenerative processes (Benilova et al., 2012; Bucciantini et al., 2002;
Ferreira and Klein, 2011; Hayden and Teplow, 2013; Sakono and Zako,
2010; Winner et al., 2011). In addition, biochemical studies have dem-
onstrated a strong correlation between the levels of soluble amyloid
oligomers in the brains of patients with AD and PD and the degree of
cognitive impairment (Ferreira et al., 2014; Winner et al., 2011). Addi-
tionally, blocking Aβ oligomerization but not fibril formation has been
shown to protect cells from toxicity (De Felice et al., 2004; Habchi et
al., 2016b) and similarly mutants of αS that promote oligomer but not
fibril formation have been reported to induce the most severe dopami-
nergic neuronal loss in the substantia nigra of animalmodels (Winner et
al., 2011). In fact, amyloid fibrils have been proposed to represent the
end stage of protein aggregation, acting as scavengers of misfolded sol-
uble oligomers that are more toxic and also resistant against degrada-
tion by proteasomes (Benilova et al., 2012).
Although the detailed mechanisms by which soluble self-assembled
oligomers could trigger toxicity remains to be established, membrane
perturbation has been proposed as a general primary step to
neurodegenetation by these aggregates. However, other cytotoxic ef-
fects of amyloid oligomers have been also proposed, including induction
of oxidative stress (De Felice et al., 2007; Deas et al., 2016), mitochon-
dria dysfunction (Devi et al., 2008; Nakamura, 2013), impairment of
the proteasome system (Xilouri et al., 2013) and blocking of trafficking
in the ER-Golgi (Cooper et al., 2006). It has been proposed generally that
oligomers are able to interact directly with and disrupt membranes, al-
though there is much to be established on the details of themechanism
of membrane disruption (Stefani and Dobson, 2003), some groups
pointing towards a pore-like mechanism (Kayed and Lasagna-Reeves,
2013; Serra-Batiste et al., 2016; Yoshiike et al., 2007) and others to
membrane destabilization without the need for the formation of specif-
ic pores in the membrane (Brender et al., 2012; Flagmeier et al., 2017;
Stockl et al., 2013; Walsh et al., 2014). In addition, other studies have
shown that some amyloid oligomers, particularly those from Aβ,
might exert their toxic effects through their interaction with specific
membrane receptors (Lauren et al., 2009; Li et al., 2011; Morkuniene
et al., 2015). Regardless of the specific mechanism of interaction, it is
well accepted that membrane perturbation by toxic soluble oligomers
can result in dysregulation of signal transduction, changes in ion ho-
meostasis in the cell, increases in intracellular calcium levels and induc-
tion of oxidative stress, likely to be a result of the entry of extracellular
calcium and redox-active metal ions into the cells due to disruption of
membrane permeability (Angelova et al., 2016; Arispe et al., 1993;
Deas et al., 2016; Pedersen et al., 2016; Quist et al., 2005; Stefani and
Dobson, 2003). Recent studies indicate that amyloid aggregates could
also induce inflammation through a receptor-mediated mechanism or
by direct interaction with the membrane (Sengupta et al., 2016). In-
flammation has long been a known component of AD and PD, and, in-
deed, inflammation is one of the earliest signs of AD, beginning prior
to the formation of visible Aβ plaques. It is, however, still unresolved
whether inflammation precedes aggregate formation or if aggregation
formation induces an inflammation response (Minter et al., 2016).
There is, therefore, continuous discussion as to whether the fibrillar
species and amyloid plaques aremore damaging than soluble oligomer-
ic species (Goure et al., 2014; Peelaerts et al., 2015) and whether or not
the former represent a sink or a source of soluble oligomeric species. In-
deed, recent studies have shown that oligomeric species can be generat-
ed via fibril disaggregation processes (Cremades et al., 2012; Kim et al.,
2008; Martins et al., 2008) and by secondary nucleation mechanisms
caused by amyloid fibrils where the fibrillar surface can catalyze theformation of oligomeric species (Cohen et al., 2013; Jeong et al., 2013).
These oligomer formation processes are likely to result in a significant
local concentration of toxic oligomers around the plaques and, given
their soluble and diffusive nature, they could easily reachdistant regions
and give rise to cellular damage; indeed, these conclusions are in agree-
mentwith in vivo studieswhere a halo of soluble oligomers surrounding
amyloid plaques has been reported (Koffie et al., 2009). In addition, re-
cent studies suggest a correlation between levels of soluble amyloid
oligomers in cerebrospinal fluid and cognitive deficits in human pa-
tients with AD (Savage et al., 2014) and PD (Horrocks et al., 2016;
Kalia et al., 2013), consistent with the view that soluble amyloid oligo-
mers interfere with synaptic function and contribute to cognitive dys-
function in these types of disease. By contrast, other studies have
suggested that the fibrillar species themselves could be highly toxic
(Luk et al., 2012; Peelaerts et al., 2015; Prusiner et al., 2015; Woerman
et al., 2015) and may be responsible for the spreading of disease by
seeding the conversion of functional soluble monomeric protein into fi-
brillar structures in the cytoplasm of recipient cells (Desplats et al.,
2009; Hansen et al., 2011; Luk et al., 2012; Peelaerts et al., 2015; Pieri
et al., 2016).
Taken together, therefore, these studies support the conclusion that
multiple protein species generated during protein amyloid aggregation,
rather than a single, discrete toxic species, exhibit neuronal toxicity
probably as a result of the triggering of different neuronal activities
and with the potential to induce different levels of toxicity, perhaps
through different types of interactions with cellular components, de-
pending on the details of their structure and the nature of the cells in
which they are formed or to which they are exposed (Campioni et al.,
2010; Cremades et al., 2012; Peelaerts et al., 2015).
4. Mechanisms of formation of amyloid aggregates
The mechanisms by which proteins convert from their functional
soluble forms into the amyloid state have been shown to be highly com-
plex and the process is known to dependonboth the intrinsic character-
istics of the protein and the environmental conditions under which
aggregation occurs. Early analysis of the kinetics of formation of amyloid
fibrils demonstrated that the overall process follows a nucleation-poly-
merization model (Jarrett and Lansbury, 1992), where soluble species
undergo a nucleation step that results in the formation of oligomeric
species that are then able to grow through further monomer addition,
eventually generating mature fibrils (Fig. 1). The growth profile of
such a process (Fig. 2, left) is characteristically sigmoidal, reflecting
the greater ease of addition ofmonomers onto existing aggregates com-
pared to the de novo formation of new oligomers directly from mono-
mers. The overall reaction rate therefore accelerates when significant
numbers of aggregates are present in solution, resulting in an initial
lag phase followed by a rapid growth phase before a plateau region is
reached when the monomer concentration becomes depleted (Cohen
et al., 2011b; Knowles et al., 2014).
There are generally two processes that generate new aggregates:
primary nucleation processes where new aggregates form at a rate de-
pendent only on the concentration of monomeric species, and second-
ary processes where new aggregates are formed at a rate dependent
on the concentration of existing fibrils (Cohen et al., 2013). The second-
ary processes that generate new aggregates can in turn be subdivided
into monomer-independent processes, such as fragmentation, and
monomer-dependent processes, such as secondary nucleation, where
the surfaces of existing fibrils catalyze the nucleation of new aggregates
from the monomeric state (Cohen et al., 2011b; Knowles et al., 2009).
Importantly, it has been observed that in some cases, surface catalyzed
nucleation can be a dominant factor in the generation of toxic oligomers
(Cohen et al., 2013).
Amyloid formation can also be seeded by the addition of pre-formed
fibrils, a phenomenon analogous to that observed in crystallization, in
which the primary nucleation step is essentially by-passed. In the
Fig. 2.Mechanism of formation of amyloid aggregates. Examples of the kinetics of formation of amyloid aggregates, including hypothetical snapshots of the ensemble of protein species
present at different phases of the aggregation process (the oligomeric species are highlightedwith red circles):A) formation of aggregates largely by primary nucleation and elongation,B)
formation of aggregates by seeding processes that bypass the primary nucleation step.
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predominant secondary processes are absent, the aggregation profile
is then expected to follow a single exponential function (Fig. 2, right)
(Cohen et al., 2011a), as a consequence of themuch slower rate (higher
energy barrier) of primary nucleation compared to the rate of addition
of monomers onto an existing fibril. An interesting property of the fibril
seeding process is that the structural features of the seeds are generally
reproduced in the growing fibrils. This phenomenon is sometimes
called templating (Serio et al., 2000), and once a template with a
cross-β structure (typically pre-formed fibrils) is introduced into a solu-
tion containingmonomeric protein,molecules ofmonomers bind to the
fibril ends and adopt the cross-β structure, becoming the next attach-
ment/templating surfaces of the fibril, again by analogy with the pro-
cesses that takes place in crystallization.
This type of seeding and templating process has been proposed to be
the basis by which the misfolded prion protein acts as an infectious
agent to propagate prion diseases (Aguzzi, 2009; Soto, 2012;
Westermark and Westermark, 2010) and is also likely to be an impor-
tant factor in the propagation of other amyloidogenic diseases
(Brundin et al., 2010; Jucker and Walker, 2011; Walker and Jucker,
2015). Although the role of amyloid spreading and propagation in dis-
ease pathogenesis wasfirst recognized to be important for the neurode-
generative diseases caused by the misfolding of prions, increasing
evidence suggests that this self-propagating activity is present in most,
or all, amyloid proteins and peptides involved in other amyloid diseases
(Walker and Jucker, 2015) and is the ultimate consequence of the
templating properties of the cross-β structure. For example, it has
been recently shown for a number of amyloid polypeptides, including
Aβ andαS, that amyloid propagationwith high structural and patholog-
ical fidelity can be triggered from exogenous sources of amyloid aggre-
gates (Lundmark et al., 2002; Peelaerts et al., 2015; Stohr et al., 2012;
Volpicelli-Daley et al., 2011), sharing analogies to the strain-specific in-
fectivity long observed for the prion proteins (Prusiner, 1991). The exis-
tence of functional prions and amyloid structures at physiological
conditions challenges the generality of this idea, as they seem to exploit
the self-assembling and templating properties of the cross-β structure
but lack pathogenicity. In these cases, however, a robust cellular control
of the aggregationmechanisms that could avoid the generation of path-
ogenic amyloid species is likely to exist (Maji et al., 2009).Moreover dif-
ferent types of behaviour will be observable under different conditions.
Thus, in a situation where the rate of secondary nucleation is very slow,
other microscopic processes (e.g. primary nucleation and elongation)
can become dominant, and the mechanism of rapid proliferation
through secondary nucleation will become negligible. Under thesecircumstances, that may be common for functional amyloid species,
the aggregation process is much more readily controlled.
In conclusion, primary and secondary aggregation pathways as well
as seeding mechanisms are likely to play important roles in disease
through the de novo formation of aggregates, the incorporation of func-
tional proteins intomisfolded states and themultiplication and prolifer-
ation of toxic aggregates that can not only damage or kill the cells in
which they form, but also invade neighbouring healthy cells and accel-
erate the conversion of soluble protein molecules into fibrils.
5. Generic features of the structure of amyloid aggregates
Amyloid fibrils are referred to as protein assemblies with a charac-
teristic cross-β architecture, in which β-strands are formed and aligned
perpendicular to thefibril axis, generating inter-molecularβ-sheets that
run the length of the aggregate. Amyloid fibrils are typically long un-
branched thread-like structures, just a few nanometers in diameter,
and composed of several protofilaments with the classic cross-β struc-
ture that twist around each other (Chiti and Dobson, 2006, 2017;
Eisenberg and Jucker, 2012; Fitzpatrick et al., 2013; Jimenez et al.,
1999, 2002; Sawaya et al., 2007; Sunde et al., 1997) (Fig. 3A). The origins
of the cross-β architecture can be attributed to the nature of the intra-
molecular and intermolecular interactions within the β-sheets, which
are dominated by hydrogen bonds between the main-chain atoms of
the polypeptide chain that are common to all peptide and protein mol-
ecules (Fandrich and Dobson, 2002; Knowles et al., 2007). A conse-
quence of this particular structure is that the spacing between strands
forming the β-sheets along the fibril axis is determined by the inter-
main chain hydrogen bonding constraints and is, therefore, indepen-
dent of the amino acid sequence of the polypeptide, and has a value
close to 4.7 Å. By contrast, the inter-sheet spacing (the spacing between
β-sheets in the direction perpendicular to the fibril axis) is variable
(typically 9–11Å) andhighly dependent on the nature of the side chains
(Fandrich and Dobson, 2002; Knowles et al., 2014). The structural vari-
ations between amyloid fibrils generated from different polypeptide
chains, therefore, arise primarily from the manner in which the various
side chains are incorporated into the cross-β structure (Fitzpatrick et al.,
2013; Jimenez et al., 1999; Serpell and Smith, 2000; Serpell et al., 2000,
1995; Zhang et al., 2009) (Fig. 3A).
The details of the characteristic structure of amyloid fibrils are also
shedding light into the details of the mechanisms by which seeding
and templating at the fibril ends occur. While the architecture of the fi-
brils is not strongly dependent on polypeptide sequence, since themain
interactions that stabilize the fibril core consist on an array of
Fig. 3. Structures of aggregates with cross-β architecture. A) Example of the structure of an amyloid fibril. The structural architecture shown in yellow is one of the polymorphs of a 11-
residue fragment of transthyretin at atomic resolution obtained by the combination of cryo-electron microscopy (cryo-EM) and solid-state NMR. Reproduced with permission from
Fitzpatrick, A.W.P. et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc. Natl. Acad. Sci. USA 110, 2013, 5468–5473 (Fitzpatrick et al., 2013). These fibrils are
made up of three filaments, each of which is formed by pairs of cross-β protofilaments. Each protofilament is composed of pairs of β-sheets that interact between each other through
specific water-mediated interactions established between the side chains of the residues of the peptide that form the core of the fibril. The scale bar in the cryo-EM image on the left
corresponds to 50 nm in length. B) Outline of the structure of a type of toxic amyloid oligomer. The figure on the right represents a three-dimensional cryo-EM image reconstruction
of a toxic oligomeric form of αS that is kinetically trapped during the formation of amyloid fibrils. The images shown in grey are representative of the side views (top) and end-on
views (bottom) of this structural class of oligomers. The images in blue show two orthogonal views, side (left) and end-on (right), of the 3D reconstruction of the oligomer, showing
the cylindrical architecture of the type observed for αS fibrils despite having only ca. 50% of the β-sheet content of the latter and a different β-strand arrangement. Reprinted with
permission from Chen, S.W. et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc. Natl. Acad. Sci. USA 112, 2015,
E1994–2003 (Chen et al., 2015).
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2012; Fitzpatrick et al., 2013; Knowles et al., 2007), self-complementary
interdigitation of the side chains between polypeptideswithin the same
β-sheet and between β-sheets have been proposed to be important to
create a tightly packed hydrophobic fibril core (Eisenberg and Jucker,
2012; Fitzpatrick et al., 2013; Luhrs et al., 2005). This packed interdigi-
tation between side chains explains both why templating between
identical polypeptide chains, rather than between differing sequences,
and the parallel in-register topology are the optimal configurations in
the amyloid fibrils where structures have been defined at present
(Fitzpatrick et al., 2013; Heise et al., 2005; Petkova et al., 2006; Tuttle
et al., 2016). In addition, in certain fibrillar structures, a slight shift be-
tween β-sheets has been observed, which leads to incompletely paired
β-strands at the fibril ends, with exposed hydrophobic residues and un-
satisfied hydrogen bonds; such features are likely to encourage the re-
cruitment of additional polypeptide chains, which, by adopting the
cross-β structure, could stabilize further the growing fibril ends, leading
to increasing extension of the fibrillar structure (Fitzpatrick et al., 2013;
Luhrs et al., 2005).
Another interesting feature of the cross-β structure is the multiplic-
ity of distinct morphologies of amyloid fibrils that a particular protein
can adopt in response to mutations in its sequence (Bolognesi et al.,
2014; Hess et al., 2007) or upon different aggregating conditions
(Gorski et al., 2001; Petkova et al., 2005), and even observed to co-
exist under the same conditions (Goldsbury et al., 2005; Heise et al.,
2005; Kad et al., 2003). The hierarchical organization of amyloid fibrils,
from the configuration and arrangement of the β-strands into β-sheets,
to the packing of the β-sheets into protofilaments and the assembly of
protofilaments into filaments and ultimately mature fibrils, gives rise
to multiple polymorphisms of amyloid assemblies that may occur at
the different stages of the self-assembly process, resulting in variations
both at the molecular and ultrastructural level of the fibril (Chiti and
Dobson, 2006, 2017; Eisenberg and Jucker, 2012). Indeed, different seg-
ments of identical polypeptides may be involved in the core structures,
resulting in fibrils with different conformational features (Colletier et
al., 2011; Lewandowski et al., 2011; Luhrs et al., 2005; Petkova et al.,
2002;Wasmer et al., 2008), and variations in the number of constituent
protofilaments and in the manner in which they interact between each
other can lead to multiple ultrastructural polymorphisms (Bauer et al.,1995; Fitzpatrick et al., 2013; Jimenez et al., 2002; Schmidt et al.,
2009; Zhang et al., 2009).
While significant advances have been made towards understanding
the structures of fibrillar aggregates, of particular significance in terms
of pathogenicity is the structural information that is beginning to
emerge for the oligomeric species that are frequently observed to accu-
mulate during the process of formation of fibrils (Bemporad and Chiti,
2012; Campioni et al., 2010; Chen et al., 2015; Cremades et al., 2017;
Kayed et al., 2003; Serra-Batiste et al., 2016). At a fundamental level,
the rapid elongation rate of small aggregates in the presence of mono-
mers makes the study of transient oligomeric species generated during
the formation of fibrils particularly challenging. The ability to produce
and isolate trapped oligomeric forms has, however, opened up the pos-
sibility of gaining insights into the nature and structure of these species
(Campioni et al., 2010; Celej et al., 2012; Chen et al., 2015; Ding et al.,
2002; Lorenzen et al., 2014b; Paslawski et al., 2014; Serra-Batiste et
al., 2016; van Rooijen et al., 2009; Volles et al., 2001).
Particular efforts have been focused on identifying the nature and
structure of oligomers of αS. A variety of procedures have been used
to trap αS oligomeric forms; some involving a change in the physico-
chemical conditions under which aggregation occurs, others involving
the covalent modification of the protein or the addition of chemical
compounds able to interact with certain types of oligomers and inhibit
their elongation and conversion into fibrils (Cremades et al., 2017).
The evident variability in the type of αS oligomeric species generated
by the different methods is highly likely to reflect the presence of mul-
tiple aggregation processes, although the data collected so far on the
various αS oligomeric species suggests that it is likely that only a rela-
tively small number of preferred self-assembly pathways exists
(Cremades et al., 2017).
We, and others, have used lyophilization as a way of trapping and
enriching samples containing one type of toxic oligomeric species
generated by αS (Celej et al., 2012; Chen et al., 2015; Gallea and
Celej, 2014; Lorenzen et al., 2014b; Paslawski et al., 2014; van
Rooijen et al., 2009), which has allowed us to obtain detailed struc-
tural and biophysical information on the nature of such species
(Chen et al., 2015). The enriched samples are composed of oligomers
with a range of sizes, with an average of approximately 25–30 pro-
tein molecules, although in some cases the size distribution of the
184 N. Cremades, C.M. Dobson / Neurobiology of Disease 109 (2018) 178–190enriched oligomers indicate that the sample contains 10–90 mers
(Chen et al., 2015; Lorenzen et al., 2014b; Zijlstra et al., 2012).
These oligomers have been found to have remarkable stability
(Chen et al., 2015; Paslawski et al., 2014) and to be able to associate
with lipid bilayers and induce membrane permeability (Chen et al.,
2015; Giehm et al., 2011; Lorenzen et al., 2014a). The β-sheet con-
tent of these oligomers is intermediate between that of the intrinsi-
cally disordered monomers and that of the fibril structure.
The core structure of the oligomers appear to involve similar res-
idues to that of the fibril, although the latter involves a larger number
of residues and has a parallel β-sheet arrangement (Celej et al., 2012;
Chen et al., 2015; Gallea and Celej, 2014), in contrast to the primarily
anti-parallel β-sheet conformation of this type of oligomer (Celej et
al., 2012; Chen et al., 2015; Gallea and Celej, 2014; Lorenzen et al.,
2014b; Paslawski et al., 2014). Interestingly, all of the information
accumulated so far on these αS oligomers indicates that they have
a remarkably high degree of similarity, in terms of physico-chemical,
structural, and toxic properties, with oligomeric species formed by
αS under different conditions and indeed other amyloidogenic pro-
teins and peptides (Bemporad and Chiti, 2012; Celej et al., 2012;
Chen et al., 2015; Danzer et al., 2007; Gallea and Celej, 2014;
Lorenzen et al., 2014b; Paslawski et al., 2014; van Rooijen et al.,
2009; Volles et al., 2001; Zijlstra et al., 2012). Indeed, the difference
in the organization of the β-sheets, from a dominance of parallel β-
sheet structure in the fibrillar form to antiparallel β-sheet structure
in stable oligomeric species, has also been reported for several
other amyloidogenic peptides and proteins such as the Aβ-peptide
(Cerf et al., 2009), lysozyme (Zou et al., 2013), a prion-related pep-
tide (Natalello et al., 2008), and β2-microglobulin (Fabian et al.,
2008).
Importantly, we found that the stable αS oligomers are toxic when
exposed to neuronal cells (Angelova et al., 2016; Chen et al., 2015;
Cremades et al., 2012: Deas et al., 2016) and reproducemost of the path-
ophysiological features of PD in model neurons (Angelova et al., 2016;
Deas et al., 2016; Devine et al., 2011). Although they are in principle
able to elongate and act as seeds for the recruitment of monomeric pro-
tein molecules, however, these oligomers appear to do so only very
slowly under physiologically-relevant conditions; indeed, the elonga-
tion rate for these oligomers under such conditions is at least three or-
ders of magnitude slower than that of the parallel β-sheet fibrillar
structures (Chen et al., 2015), a feature attributable at least in part to
the anti-parallel β-sheet structure that is predominant in these oligo-
mers (Chen et al., 2015; Qiang et al., 2012), and would need, therefore,
to undergo extensive structural reorganization in order to form stable
fibrils.
The strategy of using a wide variety of biophysical methods to study
these specificαS oligomers has enabled us to reduce their heterogeneity
to such an extent that it has been possible to begin to define their overall
structural properties andmolecular architectures. We found that all the
oligomeric species present in the sample belong to the same structural
family, differing primarily only in their size and their β-sheet content;
indeed we observed also that the β-sheet content in fact depends on
the size (the larger the oligomer, the greater the β-sheet content)
(Chen et al., 2015). Importantly, we were able to use cryo-EM image re-
construction techniques to generate a low-resolution structural model,
revealing a cylindrical architecture with a central cavity. This model
has remarkable similarities to those of mature amyloid fibrils formed
by a variety of proteins, despite their differences in morphology and
amino acid sequences (Chen et al., 2015; Chiti and Dobson, 2006). The
similarities in the architecture of the fibrillar and the oligomeric forms,
despite the differences in the organization of their β-sheet structure,
suggest, therefore, that similar types of interactions to those that stabi-
lize amyloid fibrils are likely to be responsible for the initial acquisition
of cross-β structure in the oligomeric species.Moreover, oligomeric spe-
cies, formed during fibril formation observed by TEM and AFM, with re-
markable similarities to the 3D cryo-EM model of antiparallel β-sheetoligomers have been reported forαS and other amyloidogenic polypep-
tides (Lashuel et al., 2002; Quist et al., 2005).
These species, like the antiparallel β-sheet oligomers, are also capa-
ble of binding the amyloid oligomer-specific A11 antibody and being
highly cytotoxic (Kayed et al., 2003), suggesting that the transient olig-
omeric forms generated during fibril formation,which are likely to have
an amyloid core composed primarily of parallel β-sheet, and the kinet-
ically-trapped antiparallel β-sheet oligomers could be analogous in
their global structure and represent different types of cross-β oligomer-
ic precursors. Interestingly, the A11 and other related antibodies have
also been widely used to monitor the presence of oligomers in AD
brains, and the results indicate that such oligomers are likely to exist
in vivo and to be related to pathogenicity (Hillen et al., 2010; Kayed et
al., 2007, 2003; Lacor et al., 2004; Lasagna-Reeves et al., 2012;
Noguchi et al., 2009). Indeed, some of the characteristics reported for
the toxic oligomers of αS found in vivo are very similar to those of the
β-sheet rich oligomers shown to form in vitro, both during the fibril for-
mation reaction and as a result of the lyophilization process
(Emmanouilidou et al., 2010; Feng et al., 2010; Pountney et al., 2004;
Roberts et al., 2015). All these findings suggest that the underlying ar-
chitecture reported for the αS oligomers can be adopted by different
peptides and proteins, regardless of their amino acid composition and
sequence (Chen et al., 2015), as proposed for the fibrillar structures
(Chiti and Dobson, 2006; Dobson, 2003; Eisenberg and Jucker, 2012),
and are likely to play an important role in disease.
6. Amyloid formation pathways and therapeutic strategies
The lack of efficacy of Aβ andαS immunotherapies in clinical studies
has been associated with a range of different factors, including the ex-
tent of disease progression in those patients involved in the trials. Of ad-
ditional importance, however, is undoubtedly the lack of selectivity for
themost highly toxic amyloid species involved in the initiation and pro-
gression of disease (Folch et al., 2016; Karran and De Strooper, 2016;
Sengupta et al., 2016); indeed all the antibodies currently under devel-
opment bind to either monomeric or fibrillar species or to both, and
there is likely to be in general a large excess of monomeric or fibrillar
species in the brains of AD or PD suffers relative to soluble amyloid olig-
omers. Studies have demonstrated, however, that antibodieswith selec-
tive affinity for soluble Aβ oligomers can block the toxicity associated
with these species in cell cultures (Lambert et al., 2007; Shughrue et
al., 2010) and reduce memory deficits in transgenic AD mouse models
(Hillen et al., 2010), supporting the concept that antibodies with selec-
tive affinity for specific types of amyloid oligomersmay be amore effec-
tive therapeutic strategy to block neurodegeneration.
Characterization of the oligomeric species generated during the for-
mation of amyloid fibrils is, however, very challenging, particularly as a
consequence, at any time of the reaction, of their often low populations
relative to monomeric of fibrillar species and their highly heteroge-
neous nature. In order to overcome these difficulties, a number of tech-
niques have been developed, including single-molecule methods that
enable the direct observation and characterization of individual molec-
ular species populated during the aggregation reaction (Cremades et al.,
2012; Ding et al., 2002; Orte et al., 2008; Pitschke et al., 1998). Based on
these and related studies it has become evident that multiple types of
oligomeric species are formed during the early stages of the self-assem-
bly process that leads to amyloid fibrils, and studies are beginning to
characterize their nature (Cremades et al., 2012; Iljina et al., 2016). In
particular, single-molecule fluorescence methods in which intermolec-
ular Förster resonance energy transfer (FRET) effects can be monitored
have been shown to be extremely valuable for identifying specific types
of oligomeric species and following their formation and evolution dur-
ing the early stages of protein aggregation (Cremades et al., 2012).
Investigations of the primary nucleation process of fibril formation
by αS using this methodology have revealed the existence of two im-
portant and distinct groups of oligomers. Specifically it has been found
Fig. 4. Nucleation–conversion model for the acquisition of amyloid structure during the self-assembly process of αS (Chen et al., 2015; Cremades et al., 2017, 2012). A) Schematic
nucleation-conversion model for a given pathway of amyloid formation. Monomeric αS molecules (that are intrinsically disordered) initially coalesce, probably through hydrophobic
segments of the sequence, into largely disordered oligomers (monomeric units depicted as spheres), which, after increasing in size, start to acquire the cross-β structure (depicted as
squares) once the required numbers of intermolecular hydrogen bonds are formed. Intrinsically disordered structure is represented in blue and β-sheet structure depicted in yellow.
Then, the extent of β-sheet structure in these oligomers gradually increases (squares with increasing yellow color) until the fully formed cross-β structure characteristic of the fibrillar
state is acquired. This process generates, therefore, a continuous array of oligomeric species with differing size and β-sheet content but all with the characteristic amyloid-like
structural architecture once the major structural conversion at the oligomeric level has occurred. B) A cartoon representing the main αS species observed during fibril formation by
single-molecule fluorescence experiments (Cremades et al., 2012; Iljina et al., 2016). These studies suggest that the initially formed oligomers are largely disordered, proteinase K (PK)
sensitive, and benign. They slowly convert into species rich in β-sheet structure, PK-resistant and highly toxic, through a series of structural reorganizations. Inhibiting the conversion
from disordered to β-sheet oligomers could, therefore, be a potential therapeutic strategy.
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benign oligomers, and that they subsequently convert into much more
stable oligomers, characterized by extensive β-sheet structure and a
highly toxic nature. These oligomers ultimately convert into amyloid fi-
brils by slow rearrangement (Fig. 4A) (Cremades et al., 2012; Iljina et al.,
2016) that is likely to occur through a process of sequential foldingupon
self-assembly (Cremades et al., 2017). A similar mechanism has been
proposed for the aggregation ofαS in the presence of phospholipid ves-
icles, with the rates of oligomeric conversion being comparable to those
found for the aggregation of the protein without lipid membranes
(Galvagnion et al., 2015).
The conversion from disordered to amyloid-like β-sheet oligomers
appears to be a key step in the self-assembly process that leads not
only to fibril formation but also to toxicity and resistance to degradation
by the cellular proteostasis machinery (Cremades et al., 2012) (Fig. 4B).
This conversion process is also remarkably slow indicating that the two
structurally distinct types of oligomers are likely to co-exist, particularly
at the early stages of the self-assembly process, suggesting that there
will be a significant period of time for the cellular protective machinery
to operate, for example by sequestering certain types of oligomers
(Arosio et al., 2016). This period of time (Fig. 4B) also suggests that ther-
apeutic interventionmay be viable prior to the onset of cellular damage
(Cremades et al., 2012). For such purposes, it will be of the utmost im-
portance to identify the differences between the specific physico-chem-
ical and structural features of the different aggregates in order to target
specifically the initially formed disordered oligomers and prevent their
conversion into toxic amyloid oligomers (Fig. 4B). Indeed, this systemcould form the basis for the development of the specific features that
give rise to toxicity.
The close similarity between the global architecture of the stable
toxic αS oligomers, which we have characterized in some detail (Chen
et al., 2015), and that found to be characteristic of at least a number of
disease-associated fibrils, suggests that similar types of interactions
(notably an array of inter-backbone hydrogen bonds linking the β-
strands as in thefibrillar structures (Knowles et al., 2007, 2014)) is likely
to stabilize both types of species. Consequently, a high degree of hetero-
geneity ofβ-sheet oligomerswith the same type of core architecture but
with different numbers and lengths of β-strands and different types of
β-sheet arrangements, and indeed permutations of interstrand hydro-
gen bonding interactions, are expected. Indeed, such species could be
the precursors of structurally distinct but energetically similar fibril
polymorphs that have been observed to trigger marked differences in
cellular vulnerability and pathology (Prusiner et al., 2015; Winner et
al., 2011; Woerman et al., 2015).
Some of these β-sheet-rich oligomers with a significant degree of
heterogeneity in their β-sheet content can accumulate once they are
formed as a consequence of their extremely slow rates of assembly, dis-
assembly and reorganization of cross-β structure (Cremades et al.,
2012). Thus, an array of β-sheet-rich oligomers could accumulate dur-
ing the process of amyloid self-assembly, which in turn could have
marked effects on the type and extent of toxic effects they induce in
cells. Indeed, we have proposed that differences in the arrangement of
the β-strands between certain β-sheet-rich oligomers and fibrils could
be a major reason for the very large differences between their relative
Fig. 5. Representation of a putative energy surface for the amyloid aggregation process. The energy landscape for the formation of amyloid aggregates is likely to be rugged and to be
characterized by large numbers of degenerate energy states with significant energy barriers between different regions of conformational space. The simplified free-energy surface shown
has been taken from the folding of hen lysozyme (Dinner et al., 2000) to illustrate the analogies between productive folding and misfolding and aggregation. The consequence of such a
landscape is the existence ofmultiple pathways eachwith distinct oligomeric species. Somepathwayswill generate oligomeric species that are only transient and that rapidly elongate and
convert into fibrils (e.g. the pathway depicted in yellow). But there are other pathways that generate oligomeric species that are trapped in local minima and, therefore, accumulate (e.g.,
the pathway depicted in red). These oligomers present a structural configuration that is not optimal for elongation and therefore could only transform into fibrils after major structural
rearrangements that are likely to involve partial unfolding and also to be slow (dashed red arrows).
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parallel β-sheet arrangement of the amyloid structure is readily able
to increase in length, the antiparallel β-sheet configuration appears to
have a much lower tendency to grow by further addition of monomers
(Chen et al., 2015; Petkova et al., 2004; Qiang et al., 2012). In this way, a
rearrangement of the β-strands from an antiparallel to a parallel config-
urationwould then be required for the efficient elongation of oligomers,
which have acquired predominantly an antiparallel β-sheet amyloid
configuration during the self-assembly process, in order to generate
the fibrillar amyloid architecture under physiological conditions (Fig.
5). Such a process is likely to be extremely slow, perhaps involving the
partial unfolding and disaggregation of these oligomers, a fact that
could explain the high kinetic stability that has been generally found
for antiparallel β-sheet amyloid oligomeric species (Celej et al., 2012;
Chen et al., 2015; Lorenzen et al., 2014b). The exceptional kinetic stabil-
ity of such species, together with their high thermodynamic stability
and resistance to proteolysis (Chen et al., 2015), and coupled with
their highly toxic nature (Chen et al., 2015; Lorenzen et al., 2014b;
Volles et al., 2001), make these antiparallel β-sheet amyloid oligomers
strong candidates to be key pathogenic species in the development of
disease.
By contrast, oligomeric precursors of amyloid fibrils with parallel β-
sheet architecture are likely to accumulate only transiently, as they canelongate rapidly and so generate fibrils. We propose, therefore, that the
β-sheet geometry and the rates (and energy barriers) associated with
the structural conversions between different β-sheet geometries could
play a key role in the process of the misfolding and self-association of
amyloidogenic proteins by dictating the kinetic stability and the poten-
tial toxicity of the different forms of aggregates (Chen et al., 2015). In
addition, our results have revealed an inherent multiplicity in the pro-
cess of protein misfolding with direct analogies to the multiplicity of
parallel pathways observed in the productive folding of a range of pro-
teins (Dinner et al., 2000). Such processes have been shown to result
from an initial collapse of the disordered polypeptide chains to disor-
dered structures, followed by subsequent reorganizational events that
can lead either to pathways that result in the rapid acquisition of stable
structure or to other pathways that result in the accumulation of meta-
stable intermediates (Dinner et al., 2000; Dobson, 2003) (Fig. 5). The
concept that amultiplicity of assembly steps - analogous to those of pro-
ductive folding - results in an ensemble of oligomers with differing β-
sheet arrangements, rates of elongation and inherent toxicities leads
to the interesting possibility that protein misfolding and aggregation
process in the cell can generate species with different pathological
roles depending on the nature of the stochastic processes occurring dur-
ing the self-assembly process. In addition, the elongation prone, fibril-
like oligomers with parallel β-sheet arrangement could act as key
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whereas long-lived and protease-resistant oligomers with an antiparal-
lel β-sheet arrangement could accumulatewithin cells and act as potent
toxins (Chen et al., 2015).
Our studies of αS, and those of Aβ by other groups (Bodani et al.,
2015; Liu et al., 2015), suggest, therefore, that amyloid oligomers can
form different structures or strains depending on how they acquire
structure during the early stages of the self-association process, and
that different strains of oligomers can generate differing degrees of tox-
icity. Indeed, it has recently been found in vivo that twomajor classes of
Aβ oligomers exist: one type appears likely to possess predominant par-
allel β-sheet structure and remains confined to the vicinity of the
plaques and does not impair significantly cognitive abilities. The other
type seems likely to possess anti-parallel β-sheet structure, and is
formed before the plaques are observed and is location is more highly
dispersed. In line with the conclusions drawn from our results, this
last type of oligomer has been suggested to have greater potential to
cause global neuronal dysfunction (Liu et al., 2015).
In addition, recent evidence suggests that different types of fibril-
lar strains or polymorphs of αS have different seeding capabilities
(Guo et al., 2013) and present different abilities to propagate, induc-
ing variable neuronal vulnerability and pathology (Bousset et al.,
2013; Heise et al., 2005; Peelaerts et al., 2015; Prusiner et al.,
2015), suggesting a potential link between the structure and pathol-
ogy of different αS fibrillar strains. Indeed, different fibrillar poly-
morphs or strains of αS have been related to different αS-related
pathologies such as PD, dementia with Lewy bodies and multiple
system atrophy (Peelaerts et al., 2015; Prusiner et al., 2015). Inter-
estingly, the variability in amyloid polymorphs of a given polypep-
tide has also been related to different stages in the progression of a
given amyloid disease (Thal et al., 2006).
In summary, recent studies of protein aggregation support the idea
that multiple aggregated species can be generated through diverse
misfolding pathways during the process of amyloid aggregation of a
given polypeptide chain, and also possess different degrees of neuronal
toxicity. For example, amyloid fibrils with parallel in-register topologies
are particularly efficient recruiting amyloidogenic proteins through a
self-templating process as a result of the particular properties of the
growing fibril ends. In contrast, we have found that oligomers that do
not elongate rapidly into fibrils are intrinsically more highly toxic than
their fibrillar counterparts when neuronal cells are exposed to either
of these species (Chen et al., 2015). This finding is in linewith initial ob-
servations in the prion field, in which a clear distinction between the in-
trinsically toxic species and the species that propagates pathology has
been suggested (Sandberg et al., 2011). It, therefore, seems reasonable
that different types of aggregates populated during the process of self-
assembly of a given protein could be involved in different stages of the
development of a particular pathology, some species being directly in-
volved in the induction of neurotoxicity and others in the propagation
of pathology (Chen et al., 2015).
The ability to identify the structural features of the specific species
involved in the distinct pathological processes would not only provide
important insights into the mechanisms of the generation of toxicity
but could also be of great value in the design of effective therapeutic
and diagnostic approaches that rely on specific protein conformations.
For example, we could potentially design antibodies or small molecules
that target specific protein species in order to inhibit specific key steps
in the process of aggregation, to reduce the ease of conversion of the
protein into pathological conformations, to reduce the toxicity of the
pathogenic protein species or to increase their selective clearance.
Two examples of small molecules with potential therapeutic interest
have been recently reported following these ideas: one representing
an approach in which small molecules can be designed to inhibit specif-
ic steps in the aggregation reaction (Habchi et al., 2016a, b), and another
representing an approach inwhich the oligomer toxicitywas in addition
significantly reduced by binding to a small molecule (Perni et al., 2017).Importantly, and in the light of the recent findings, combination of
methods that target simultaneously or sequentially different protein
species might be needed to prevent fully the toxicity associated with
the multiple pathogenic processes that occur during the development
and progression of the disease.
In general, fundamental biophysical and structural studies of protein
aggregation are already contributing to the development of new ap-
proaches to identify effective strategies for the treatment of amyloid
disease. The combination of therapies targeting different forms of
toxic amyloid aggregates of a given polypeptide chain, perhaps along
with anti-inflammatory treatments that could act synergistically,
could together target a range of key pathological pathways in these
types of multifactorial disease. To achieve this objective, a detailed un-
derstanding of the conformational species that are particularly toxic
under different conditions will be a key factor in the effective develop-
ment of targeted drug therapeutics.
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